Wegovy Coupons in 2026: Every Discount Option, Ranked by What You Actually Save

Key Takeaways

• The official Novo Nordisk Wegovy savings card brings most commercial-insurance patients to $0 to $225 per 28-day fill, with annual savings cap of $4,600.
• For patients without commercial insurance, the WegovyDirect cash-pay option lists Wegovy at about $499 per month for the all-dose subscription, per April 2026 manufacturer pricing.
• Medicare and Medicaid patients cannot use the savings card. Some Medicare patients qualify for Wegovy under the cardiovascular indication.
• Third-party coupon sites such as GoodRx do not offer meaningful Wegovy discounts because Wegovy is brand-only and rarely prices below the manufacturer programs.
• Patient assistance through Novo Nordisk's PAP can provide free Wegovy to qualifying low-income patients with no insurance coverage.

Direct answer (40-60 words)

The main Wegovy coupon is the Novo Nordisk savings card, which brings most commercial-insurance patients to $0 to $225 per 28-day fill, capped at $4,600 a year. Patients without commercial coverage can pay about $499 a month through WegovyDirect, per April 2026 pricing. Low-income patients may qualify for free Wegovy through Novo Nordisk's Patient Assistance Program.

Table of contents

1. The 30-second answer
2. The Wegovy savings card: who qualifies and what it costs
3. WegovyDirect cash-pay program
4. Medicare and Medicaid: why the card doesn't apply
5. Patient Assistance Program for uninsured low-income patients
6. Why GoodRx and similar coupon sites don't help with Wegovy
7. The role of HSA and FSA dollars
8. What to do when no coupon brings the price into reach
9. Step-by-step: lowest possible Wegovy price for your situation
10. FAQ
11. Sources
12. Footer disclaimers

The Wegovy savings card: who qualifies and what it costs

The Novo Nordisk Wegovy savings card is the main "coupon" most patients are looking for. As of April 2026, the published terms are:

• Eligibility: US residents with commercial (private/employer) insurance that covers Wegovy.
• Pay as little as $0 per 28-day fill if your insurance covers Wegovy.
• Pay as little as $225 per 28-day fill if your insurance does not cover Wegovy but you have commercial coverage for some prescriptions.
• Maximum savings: $225 per fill if insurance doesn't cover Wegovy. Up to $500 per fill if insurance does cover but copay is high.
• Annual benefit cap: Approximately $4,600 in total savings per calendar year.
• Excluded: Medicare, Medicaid, Tricare, VA, and any other federal or state-funded coverage.

The card stacks with insurance. Insurance pays its contracted portion first, the card covers part of the remaining cost, and you pay the floor copay. If insurance denies coverage entirely, the card can still apply at the $225 cash-floor level, but only for commercially insured patients.

Activation takes a few minutes online at the Wegovy website. The card produces a BIN, PCN, and group number that the pharmacy enters at point of sale.

A common pitfall: the card doesn't help patients on Medicare even though some Medicare patients have supplemental commercial coverage. Once any portion of the prescription benefit is funded by Medicare, the card is excluded.

WegovyDirect cash-pay program

For patients without commercial insurance, or patients whose insurance refuses to cover Wegovy and who don't want to pay full retail, Novo Nordisk launched WegovyDirect (a self-pay channel through NovoCare Pharmacy).

Per April 2026 published pricing:

Plan	What you get	Monthly cost
WegovyDirect (all doses)	Any Wegovy dose, ships monthly	About $499 per 28-day supply
Higher-dose plans	1.7 mg or 2.4 mg specifically	Same about $499

Mechanics:

• Order through the WegovyDirect online portal
• Telehealth consult (separate fee may apply if you don't have an existing prescription)
• Ships from a Novo Nordisk-affiliated pharmacy
• Monthly auto-refill subscription
• Cash payment, no insurance billing

The $499 list represents about a 50% discount from the standard cash list price for Wegovy, which runs roughly $1,350 a month at retail pharmacies. WegovyDirect's main competitor is compounded semaglutide through telehealth platforms, which often costs less but is not FDA-approved and is not interchangeable with Wegovy.

For patients who want brand-name FDA-approved Wegovy and don't have insurance coverage, WegovyDirect is currently the lowest-cost legitimate option. The $499 number is fixed regardless of dose, which is unusual for prescription pricing.

Medicare and Medicaid: why the card doesn't apply

Federal anti-kickback rules prohibit drug manufacturers from offering copay coupons or savings cards to Medicare, Medicaid, Tricare, or VA patients. The reasoning: these patients' drugs are partly funded by federal dollars, and a manufacturer paying part of the patient's copay would be seen as steering the patient toward the manufacturer's drug at federal expense.

This means:

• A 67-year-old retiree on Medicare Part D cannot use the Wegovy savings card, period.
• A 45-year-old on Medicaid cannot use the card.
• A military family member with Tricare cannot use the card.

Medicare exception for cardiovascular Wegovy.

Wegovy received an FDA label expansion in March 2024 to reduce the risk of major adverse cardiovascular events in adults with overweight or obesity plus established cardiovascular disease. CMS issued guidance allowing Medicare Part D plans to cover Wegovy for this specific indication. Patients with documented CV disease (prior heart attack, stroke, or peripheral artery disease) plus BMI 27+ can request Wegovy coverage under their Part D plan.

This is the only meaningful Medicare coverage path for Wegovy as of April 2026. Coverage is plan-specific and requires prior authorization documenting the CV history. Copays vary widely (typically $40 to $200 a month) and the new Inflation Reduction Act $2,000 annual out-of-pocket cap applies.

Medicaid coverage.

A handful of state Medicaid programs cover Wegovy for obesity. Most do not. Each state Medicaid sets its own preferred drug list. Coverage criteria when offered usually include BMI 30+ (or 27+ with comorbidity), documented prior weight-loss attempts, and provider certification.

If your state Medicaid does not cover Wegovy, the savings card cannot fill the gap because Medicaid is excluded.

Patient Assistance Program for uninsured low-income patients

The Novo Nordisk Patient Assistance Program (PAP) provides free Wegovy to qualifying low-income patients. Eligibility criteria as of April 2026:

• US resident or legal alien
• Total household income at or below 400% of federal poverty level (about $60,240 for one person, $124,800 for a family of four)
• No prescription drug coverage, or coverage that doesn't include Wegovy and won't be made to cover it
• Not covered by Medicare, Medicaid, or other federal/state programs that would pay for the drug

Approval typically lasts 12 months and is renewable. Approved drug ships to the patient's provider's office. The PAP for Wegovy specifically tends to have stricter income verification than the broader Novo Nordisk PAP, and approval rates are lower than for diabetes-indicated Ozempic.

For patients clearly meeting income criteria with no insurance and a documented obesity diagnosis (BMI 30+, or 27+ with comorbidity), the PAP is worth applying to. The application requires provider involvement and tax documentation of household income.

Why GoodRx and similar coupon sites don't help with Wegovy

GoodRx, SingleCare, Optum Perks, and similar pharmacy discount card services typically negotiate prices below cash retail by routing prescriptions through a PBM. They work well for generics and many older brand drugs, but they don't move the needle much for newer brand-only drugs like Wegovy.

Why:

• No generic exists. GLP-1s are still patent-protected. Discount card services rely heavily on generic substitution, which isn't an option here.
• Manufacturer rebate structure. Novo Nordisk's rebates flow to insurance plan PBMs, not to retail discount card programs. Retail discount card programs can't access those rebates.
• The manufacturer programs already discount. WegovyDirect at $499 a month is already a meaningful discount from cash list. GoodRx-style programs typically offer at best a few percent off of full retail Wegovy, which is still way above WegovyDirect's price.

If you check GoodRx for Wegovy, you'll usually see prices of $1,250 to $1,400 a month, which is essentially the cash retail price with a small discount. WegovyDirect at $499 is the lower bar to beat for cash-pay patients.

For a patient with no insurance, the order of preference is:

1. Apply for Novo Nordisk PAP if income qualifies (could be free)
2. Use WegovyDirect at $499 a month if PAP isn't an option
3. Consider a state-licensed compounding pharmacy for compounded semaglutide (not FDA-approved, not interchangeable with Wegovy)
4. As a last resort, retail with a discount card

The role of HSA and FSA dollars

Wegovy is HSA- and FSA-eligible when prescribed for a qualifying medical condition. For commercial-insurance patients with high-deductible health plans, this matters more than it sounds.

How HSA helps:

• HSA contributions are pretax, federal-tax-free at withdrawal for qualified medical expenses, and (in most states) state-tax-free.
• A patient in a 24% federal bracket effectively gets a 24% discount on out-of-pocket Wegovy costs paid through HSA dollars.
• Annual HSA contribution limits in 2026: $4,300 for individual, $8,650 for family, plus $1,000 catch-up at age 55+.

For a patient paying $200 a month out of pocket on Wegovy ($2,400 a year), running that through HSA is roughly equivalent to a $576 a year discount in a 24% bracket.

FSA works similarly with lower limits. Wegovy expenses must be incurred during the FSA plan year and submitted with proof of prescription.

What to do when no coupon brings the price into reach

If you've checked all of the above and Wegovy is still unaffordable, options narrow but don't disappear:

• Reapply for insurance coverage. Insurance denials are often overturnable. Document failed prior weight-loss attempts and BMI history.
• Check whether you qualify for the cardiovascular indication. If you have a history of MI, stroke, or peripheral artery disease plus BMI 27+, the Wegovy CV indication may open Medicare or insurance coverage.
• Consider compounded semaglutide. Available through state-licensed compounding pharmacies in response to an individual prescription. Compounded semaglutide is not FDA-approved, is not interchangeable with Wegovy, and pricing varies by provider. Quality varies between pharmacies; ask about USP 797 compliance and licensure status.
• Consider compounded tirzepatide. A different molecule with larger weight-loss results in trials. Same regulatory caveat.
• Wait for generic semaglutide. Patent expirations are still several years out for semaglutide in the US. This is not a near-term solution.

Most patients land on the savings card or WegovyDirect path. The PAP path applies to a narrower group.

Step-by-step: lowest possible Wegovy price for your situation

If you have commercial insurance:

1. Check whether your plan covers Wegovy. Call member services or check the plan formulary.
2. If covered, get the savings card and use it. Typical cost: $0 to $225 per fill.
3. If not covered, request a formulary exception or appeal. Provider's office handles this.
4. If the appeal fails, use the savings card at the $225 cash-floor level (still works for commercially insured patients even if your specific plan doesn't cover Wegovy).
5. Compare with WegovyDirect at $499 to see which is lower.

If you have Medicare Part D:

1. Check whether you qualify for the cardiovascular indication (history of MI, stroke, or PAD plus BMI 27+).
2. If yes, request Wegovy coverage through your Part D plan with prior authorization documenting CV history.
3. If approved, expect copays of $40 to $200 a month. The $2,000 annual out-of-pocket cap applies.
4. If not eligible, Wegovy is not covered. Look at WegovyDirect at $499 a month or compounded semaglutide as cash-pay options.

If you have Medicaid:

1. Check your state's preferred drug list for Wegovy coverage. Most states do not cover.
2. If covered, expect $0 to $10 copays.
3. If not covered, the savings card cannot apply. WegovyDirect is the cleanest cash-pay option at $499.

If you have no insurance:

1. Apply for Novo Nordisk PAP if household income is at or below 400% FPL.
2. If approved, free drug ships to your provider's office.
3. If not approved, use WegovyDirect at $499 a month or consider compounded options through a state-licensed compounding pharmacy.

FAQ

Are there real Wegovy coupons in 2026? Yes. The Novo Nordisk Wegovy savings card is the main coupon. Commercial-insurance patients with covered Wegovy can pay as little as $0 per fill, capped at $4,600 of savings per year. Patients without coverage can pay about $225 per fill at the cash-floor level.

Why do so many Wegovy coupon codes online not work? Most "coupon codes" floating around online refer to the manufacturer savings card, which is free and self-service. Unofficial coupon sites often relist the official program with affiliate links. The official terms only come from Novo Nordisk.

How much is Wegovy at a pharmacy with the savings card? With commercial insurance covering Wegovy, the card typically brings cost to $0 to $225 per 28-day fill. Without insurance covering Wegovy but with commercial coverage, the card holds at $225 per fill at the cash-floor level. Excludes Medicare, Medicaid, Tricare, VA.

Is WegovyDirect cheaper than the savings card? Depends. With commercial insurance covering Wegovy, the savings card typically beats WegovyDirect ($0 to $225 vs $499). Without insurance coverage, WegovyDirect at $499 may beat the card's $225 floor only when factoring all costs. Compare both for your situation.

Can Medicare patients get a Wegovy coupon? The savings card is excluded for Medicare patients. Some Medicare Part D plans now cover Wegovy under the cardiovascular indication for eligible patients. The Inflation Reduction Act $2,000 annual out-of-pocket cap helps with high copays once it's hit.

Does GoodRx work for Wegovy? Not effectively. GoodRx and similar discount cards usually price Wegovy near full retail ($1,250 to $1,400 a month). The Novo Nordisk programs (savings card, WegovyDirect, PAP) offer better discounts in nearly every scenario.

Can I stack a Wegovy coupon with insurance? Yes. The savings card stacks with commercial insurance. Insurance pays first, card pays a portion, you pay the remaining floor copay (often $0 to $225). The card cannot stack with Medicare, Medicaid, or Tricare.

Is the Wegovy savings card limited per year? Yes. As of April 2026, the annual savings cap is approximately $4,600. Once you've saved that much in a calendar year, the card stops applying and you pay the full insurance copay until January 1.

How do I sign up for the Wegovy savings card? Go to the Wegovy website, click savings card, fill out the brief eligibility form, and you'll get a card number, BIN, PCN, and group number. Bring the card to the pharmacy. Activation is free and takes 2 minutes.

Can I use HSA dollars for Wegovy? Yes. Wegovy is HSA- and FSA-eligible when prescribed for a qualifying medical condition. Paying out of pocket through HSA effectively discounts your Wegovy cost by your federal tax bracket plus any state tax savings.

What if I can't afford Wegovy at any of these prices? Apply for Novo Nordisk PAP (free if income at or below 400% FPL with no coverage). Consider compounded semaglutide through a state-licensed compounding pharmacy (not FDA-approved, not interchangeable with Wegovy). Talk with your provider about generic liraglutide or other covered alternatives.

Will my employer plan cover Wegovy in 2026? Coverage rates are growing. About 30% of commercial plans cover Wegovy for weight loss alone, and a higher share cover it for cardiovascular indication. Check your specific plan's formulary or call HR. Self-funded employer plans set their own rules.

Sources

1. Novo Nordisk. Wegovy prescribing information, revised 2024.
2. Novo Nordisk. Wegovy savings card terms and conditions, April 2026.
3. Novo Nordisk. WegovyDirect program details, April 2026.
4. Novo Nordisk Patient Assistance Program eligibility, April 2026.
5. Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023;389:2221-2232.
6. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989-1002.
7. Centers for Medicare & Medicaid Services. Memo on Wegovy coverage under Medicare Part D for cardiovascular indication, March 2024.
8. Centers for Medicare & Medicaid Services. Inflation Reduction Act drug pricing provisions, 2025 implementation.
9. Office of Inspector General, HHS. Special advisory bulletin on offering gifts to Medicare and Medicaid beneficiaries.
10. Internal Revenue Service. Publication 502, medical and dental expenses, 2025.
11. Kaiser Family Foundation. Coverage of GLP-1s for obesity in commercial plans, 2025 analysis.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy and Ozempic are registered trademarks of Novo Nordisk A/S. GoodRx is a registered trademark of GoodRx Holdings, Inc. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.